CN1178935C - 用作α-2-肾上腺素受体拮抗剂的1,3-二取代吡咯烷 - Google Patents

用作α-2-肾上腺素受体拮抗剂的1,3-二取代吡咯烷 Download PDF

Info

Publication number
CN1178935C
CN1178935C CNB018042341A CN01804234A CN1178935C CN 1178935 C CN1178935 C CN 1178935C CN B018042341 A CNB018042341 A CN B018042341A CN 01804234 A CN01804234 A CN 01804234A CN 1178935 C CN1178935 C CN 1178935C
Authority
CN
China
Prior art keywords
alkyl
hydrogen
formula
compound
free alkali
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018042341A
Other languages
English (en)
Other versions
CN1396920A (zh
Inventor
Mp
M·P·塞勒
J·诺祖拉克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1396920A publication Critical patent/CN1396920A/zh
Application granted granted Critical
Publication of CN1178935C publication Critical patent/CN1178935C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/08—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

本发明提供了式(I)化合物及其制备方法，其中R0，R1，R2和A如说明书所定义。式(I)化合物对α2肾上腺素受体具有高亲和性且因此可用作药物。

Description

用作α-2-肾上腺素受体拮抗剂的1，3-二取代吡咯烷
本发明涉及新的1，3-二取代吡咯烷、其制备、其作为药物的用途和含有它们的药物组合物。
更确切地说，本发明提供一种呈游离碱或酸加成盐形式的式I化合物
其中
R0是氢或(C1-4)烷基，
R1是卤素、羟基、(C1-4)烷基、(C1-4)烷氧基、(C2-5)链烯氧基、三氟甲基或三氟甲氧基，且如果A是式(b)、(c)、(f)或(g)的基团，R1也可以是氢，
R2是氢或如R1所定义，或者当处在R1的邻位时也可以与R1形成亚甲二氧基，和
A是四氢吡喃-4-基或下式所示基团
或
Figure C0180423400044
其中
m是1-3，
X是O、S或CH＝CH，
R3是氢、卤素、羟基、(C1-4)烷基、羟基(C1-4)烷基、(C1-4)烷氧基、三氟甲基、(C1-4)烷基磺酰氨基、苄氧基、氨基甲酰基、(C1-4)烷基氨基甲酰基或二(C1-4)烷基氨基甲酰基，
R4和R5是氢、卤素、(C1-4)烷基或(C1-4)烷氧基，
R6是氢、卤素或(C1-4)烷基，
R7是氢、(C1-6)烷基或(C3-7)环烷基(C1-4)烷基，
R8是氢、卤素、羟基、(C1-4)烷基、(C1-4)烷氧基、氨基、(C2-5)链烷酰基氨基、苯甲酰氨基、(C1-4)烷基磺酰氨基、苄基磺酰氨基、呋喃基羰基氨基、氨基甲酰基、(C1-4)烷基氨基甲酰基或二(C1-4)烷基氨基甲酰基，和
R9是氢、卤素、(C1-4)烷基或苯基，或
R8和R9一起为-O-(CH2)m-O-，其中m定义如上，
R10是氢、(C1-4)烷基、(C3-6)环烷基(C1-4)烷基、(C1-4)烷基羰基、(C3-6)环烷基羰基、(C1-4)烷氧羰基、苄基、苄氧基羰基、苯甲酰基、(C1-4)烷基磺酰基、苯磺酰基、苄基羰基、苄基磺酰基、2-呋喃基羰基氨基或N-(C1-4)烷基-N-(2-呋喃基羰基)氨基，和
R11是氢或(C1-4)烷氧基。
由于式I化合物及其盐中存在不对称碳原子，所以这些化合物可以旋光活性形式或旋光异构体的混合物形式存在，例如外消旋混合物形式。所有旋光异构体及其包括外消旋混合物的混合物都是本发明的一部分。
卤素指氟、氯、溴或碘，优选氟或氯。
任何烷基和烷氧基都是支链或直链基团。优选甲基或甲氧基。
本发明另一方面提供一种生产式I化合物及其盐的方法，其中烷基化式II化合物
Figure C0180423400051
其中R1和R2的定义同上，
并以游离碱或酸加成盐形式回收所得化合物。
烷基化可依照传统程序进行，例如使用适当的式Y-CHR0-A化合物，其中R0和A定义如上，Y为碘、溴、氯、甲磺酰氧基或甲苯磺酰氧基，该烷基化在碱存在下和在惰性溶剂中，优选在高温下，如实施例1所述进行。另外可以例如如实施例4所述使用R0-CO-A，其中R0和A定义如上(还原烷基化)。对于其中R0是氢的式I化合物的制备，烷基化还可以通过用酸A-COOH(其中A定义如上)酰化，然后还原而进行，例如如实施例2所述。
对于其中A是式(c)或(e)基团的式I化合物的制备，取代基R7或R10可以在式II化合物烷基化或酰化/还原之后适当地引入，例如如实施例3所述。
其中A定义如上但没有可还原官能团(以下写作A’)的式I化合物也可以通过还原式III化合物获得
其中R0，R1，R2和A’定义如上，式III化合物由式IV的二酸与胺H2N-CHR0-A’(其中R0和A’定义如上)闭环而获得
Figure C0180423400062
其中R1和R2定义如上。
依照上述方法得到的反应混合物的加工和由此得到的化合物的纯化可以按照已知方法进行。
旋光纯形式的式I化合物可由相应的外消旋体通过熟知的方法获得，或使用旋光纯的起始原料，例如如实施例2-5所述。
酸加成盐可用已知的方法由游离碱生产，反之亦然。
式II，IV，Y-CHR0-A和H2N-CHR0-A的起始化合物是已知的，或可以使用传统方法由已知化合物获得。
式I化合物及其可药用的酸加成盐，以下称为本发明试剂，当进行体外和动物试验时显示出有价值的药理性能，因此可用作药物。
在结合分析中，本发明试剂对α2肾上腺素受体亚型显示出高的亲和性，对α2C具有选择性，正如在使用3H-RX821002作为配体和来自表达重组人α2肾上腺素受体亚型的CHO K1细胞的膜所作的放射性配体结合分析所显示的。在该分析中，本发明试剂显示的pKd值为约6-约10。
在使用基于稳定表达重组人α2受体的转染的CHO K1细胞的cAMP基荧光素酶报告基因分析的体外拮抗剂实验中，在α2拮抗剂UK 14，304或去甲肾上腺素的存在下，本发明试剂是α2受体的竞争性拮抗剂且具有约6-约9的pKB值。
在体外，剂量为皮下约0.3-约30mg/kg时，本发明试剂能抑制洛沙平引起的大鼠强直性昏厥[参看Kalkman H.O.等人.，《英国药理学杂志》(Br.J.Pharmacol.)124：1550-1556(1998)]。
此外，本发明试剂在剂量为皮下约0.3-约30mg/kg时能够抑制苯丙胺引起的大鼠运动。运动(走动性活动)以t＝0皮下注射苯丙胺(1mg/kg)或溶剂(生理盐水)后即刻起15分钟周期内在合适装置内的连续红外中断次数测量。化合物或溶剂在t＝-30分钟时施用。
如上所述，本发明试剂可作为抗精神病药用于治疗下列疾病：精神分裂症、抑郁症(包括双极情感障碍)和一般地任何与中枢或外周神经系统中缺乏去甲肾上腺素有关的疾病，例如认知缺陷、帕金森氏病、药物滥用、注意力缺乏多动症、青光眼、糖尿病和勃起障碍，其中所述缺乏由α-拮抗剂通过突触前α2受体的阻断补偿。
对于上面提到的适应症，合适的剂量当然要根据例如所用的化合物、宿主、给药模式和所治疗疾病的性质和程度变化。但是，令人满意的动物试验结果一般在日剂量为约0.1-约100，优选约0.5-约100mg/kg动物体重下获得。在较大的哺乳动物如人类中，需要的日剂量范围为约1-约500、优选约1-约300mg的本发明试剂，以方便方式给药，例如一天分成至多4次或以缓释的方式。
本发明试剂可以任何传统方式给药，特别是肠内给药，优选口服，例如以片剂或胶囊的形式，或肠胃外给药，例如以可注射溶液或悬浮液的方式。
根据前述，本发明还提供一种本发明试剂，用作例如治疗精神分裂症的药物。
本发明进一步提供一种含有与至少一种药物载体或稀释剂结合的本发明试剂的药物组合物。此组合物可以传统方式制造。单位剂形含有例如约0.25-约150、优选0.25-约25mg的本发明化合物。
对于所有上述适应症，优选的化合物是(R)-1-异丙基-5-[3-(2-甲氧苯基)吡咯烷-1-基甲基]-1H-吡啶-2-酮和(R)-1-(2，3-二氢-苯并-[1，4]二噁烯-6-基甲基)-3-(2-甲氧苯基)吡咯烷。在上述的洛沙平引起的强直性昏厥试验中，在皮下0.3-3mg/kg剂量下，两种化合物都显示持续时间长的、剂量依赖性强直性昏厥抑制。口服剂量10mg/kg产生与皮下3mg/kg类似的抑制。在上述的苯丙胺引起的运动试验中，在剂量分别为皮下0.1、0.3和1mg/kg(首先提到的化合物)和皮下1、3和10mg/kg(第二种化合物)时，两种化合物剂量依赖地减少运动。
优选的适应症是精神分裂症和抑郁症。
此外，本发明提供本发明试剂在制造用于治疗上述任何疾病的药物中的用途。
更进一步，本发明提供一种在需要治疗的个体中治疗任何上述疾病的方法，该方法包括向该个体给予治疗有效量的本发明试剂。
下面实施例说明本发明。所给的温度为摄氏温度并且未作修正。
实施例1：1-(1.4-二氧杂螺[4.5]癸-8-基甲基)-3-(2-甲氧苯基)吡咯烷
将1g3-(2-甲氧苯基)吡咯烷溶于60ml二噁烷和0.85g NaI，接着加入溶于5ml二噁烷的1.2mlN，N-乙基二异丙基胺和1.5g8-溴代甲基-1.4-二氧杂螺[4.5]癸烷。反应混合物80℃过夜搅拌，蒸发后残余物依次用乙酸乙酯/2N Na2CO3、NaCl水溶液萃取。干燥和蒸发合并的有机相后产生一油状残余物，该残余物使用叔丁基甲基醚作为溶剂体系通过硅胶快速色谱法提纯提供一种油状产品。MS(EI)：M+＝331：NMR(DMSO)：1.1(2H，m)，1.45(3H，m)，1.6-1.8(5H，m)，2.15(1H，m)，2.25(2H，m)，2.4(1H，t)，2.6(2H，m)，2.8(1H，t)，3.6(1H，t)，3.75(3H，s)，3.85(4H，s)，6.9(2H，dd)，7.15(1H，t)，7.3(1H，d)。
实施例2：(+)-5-[3-(2-甲氧苯基)吡咯烷-1-基甲基]-1H-吡啶-2-酮
在0°温度下，将溶于100ml四氢呋喃(THF)中的10.5g(-)-5-[3-(2-甲氧苯基)吡咯烷-1-羰基]-1H-吡啶-2-酮加入6.7gLiAlH4在200ml四氢呋喃(THF)的悬浮液中。反应混合物的温度允许达到室温同时连续搅拌17小时。随后，反应混合物用NH4Cl溶液水解并过滤。滤液经蒸发后先在CH2Cl2和1N Na2CO3之间分配，接着用NaCl水溶液分配。合并的有机相干燥和蒸发后得到的油用9/1比例的CH2Cl2/MeOH为溶剂体系通过硅胶快速色谱法提纯以提供一种油状产品：[αD 25]＝+31.4°(c＝1.0，EtOH)；MS(EI)：M+＝284；NMR(DMSO)：1.75(1H，m)，2.15(1H，m)，2.4(1H，t)，2.6(2H，m)，2.8(1H，t)，3.3-3.4(2H，m)，3.6(1H，m)，3.75(3H，s)，6.3(1H，d)，6.85-6.95(2H，m)，7.15(1H，t)，7.2(1H，s)，7.25(1H，d)，7.45(1H，dd)，11.4(1H，s)。
起始物(-)-5-[3-(2-甲氧苯基)吡咯烷-1-羰基]-1H-吡啶-2-酮的制备过程如下：
将6.26g6-羟基烟酸悬浮于300ml的DMF和9.3g的N，N’-二环己基碳二亚胺中，之后加入6.1g1-羟基苯并三唑。室温搅拌30分钟后，将溶于45mlDMF中的8.0g(-)-3-(2-甲氧苯基)吡咯烷加入得到的溶液中并过夜连续搅拌。滤除二环己基脲后，蒸发得到的滤液，将残余物先在乙酸乙酯和2NHCL之间分配，然后用NaCl水溶液分配。合并的有机相干燥和蒸发后得到的残余物用比例为95/4.5/0.5的CH2Cl2/MeOH/浓NH4OH水溶液为溶剂体系通过硅胶快速色谱法提纯以提供一种白色泡沫产品：[αD 25]＝-34.7°(c＝1.0，EtOH)；MS(CI)：MH+＝299；NMR(DMSO)：2.05(1H，m)，2.15(1H，m)，3.45-3.9(8H，m)，6.35(1H，d)，6.9-7.05(2H，m)，7.25(2H，m)，7.65(1H，dd)，7.75(1H，s)，11.9(1H，s)。
实施例3：(+)-1-异丙基-5-[3-(2-甲氧苯基)吡咯烷-1-基甲基]-1H-吡啶-2-酮和 (+)-2-异丙氧基-5-[3-(2-甲氧苯基)吡咯烷-1-基甲基]-1H-吡啶
将9.75g(+)-5-[3-(2-甲氧苯基)吡咯烷-1-基甲基]-1H-吡啶-2-酮(实施例2)溶于170ml甲苯。先加入14.2g的Na2CO3，然后加入6.9ml的异丙基碘，在100°过夜搅拌溶液。随后再加入3.4g异丙基碘并另外连续搅拌17小时。反应溶液用水萃取，合并的有机相干燥和蒸发后得到油状残余物，该残余物以95/4.5/0.5比例的CH2Cl2/MeOH/浓NH4OH水溶液为溶剂体系通过硅胶快速色谱法提纯以提供(+)-1-异丙基-5-[3-(2-甲氧苯基)吡咯烷-1-基甲基]-1H-吡啶-2-酮{[αD 25]＝+19.7°(c＝1.0，EtOH)；MS(CI)：MH+＝327；NMR(DMSO，120°)：1.3(6H，d)，1.95(1H，m)，2.3(1H，m)，2.7-3.4(4H，m)，3.6-3.8(3H，m)，3.8(3H，s)，5.0(1H，q)，6.35(1H，d)，6.9-7.0(2H，m)，7.2(1H，t)，7.3(1H，m)，7.4(1H，m)，7.6(1H，m)}和(+)-2-异丙氧基-5-[3-(2-甲氧苯基)吡咯烷-1-基甲基]-1H-吡啶{[αD 25]＝+22.8°(c＝1.0，EtOH)；MS(EI)：M+＝326；NMR(DMSO)：1.3(6H，d)，1.75(1H，m)，2.15(1H，m)，2.4(1H，t)，2.65(2H，m)，2.8(1H，t)，3.5-3.65(3H，m)，3.75(3H，s)，5.2(1H，m)，6.7(1H，d)，6.85-6.95(2H，m)，7.15(1H，t)，7.3(1H，d)，7.6(1H，m)，8.05(1H，s)}
实施例4：(+)-1-(2，3-二氢苯并[1.4]二噁烯-6-甲基)-3-(2-甲氧苯基)吡咯烷
将1.77g(-)-3-(2-甲氧苯基)吡咯烷和1.8g2，3-二氢苯并[1.4]-二噁烯-6-甲醛先后溶于40ml MeOH。加入1.26gNaCNBH3并在室温搅拌反应混合物3小时。蒸发溶剂后残余物在乙酸乙酯和水之间分配。合并有机相，干燥和蒸发，将所得油状残余物以1/9比例的乙酸乙酯/己烷为溶剂体系通过硅胶快速色谱法提纯。以油状物得到产品，将其转换成盐酸盐：mp201-202°；[αD 20]＝+9.7°(c＝1.0，MeOH)；MS(ES)：MH+＝326；NMR(DMSO/NaOD)：1.7(1H，m)，2.15(1H，m)，2.35(1H，q)，2.6-2.7(2H，m)，2.8(1H，t)，3.45(1H，q)，3.55(1H，q)，3.75(3H，s)，4.2(4H，s)，6.75-6.95(5H，m)，7.15(1H，t)，7.25(1H，d)。
实施例5：(-)-2-[1-(2，3-二氢苯并[1.4]二噁烯-6-基甲基)吡咯烷-3-基]苯酚
将450mg(-)-2-吡咯烷-3-基苯酚和520mg2，3-二氢苯并[1.4]二噁烯-6-甲醛先后溶于10ml MeOH。在分批加入443mg NaCNBH3之前，加入乙酸将pH调节为5.5并搅拌反应溶液2小时。过夜连续搅拌，随后蒸发溶剂并以比例为95/4.5/0.5的CH2Cl2/EtOH/浓NH4OH水溶液通过硅胶快速色谱法提纯残余物以提供一种油状产品：[αD 20]＝-35.6°(c＝0.75，EtOH)；MS(EI)：M+＝311；NMR(DMSO)：1.7(1H，m)，2.2-2.4(2H，m)，2.6(1H，t)，2.75(1H，dd)，2.95(1H，t)，3.4(1H，m)，3.6(2H，q)，4.25(4H，s)，6.65(1H，t)，6.7(1H，d)，6.75-6.85(3H，m)，6.95-7.05(2H，m)。
起始物(-)-5-[3-(2-甲氧苯基)吡咯烷-1-羰基]-1H-吡啶-2-酮的制备过程如下：
将500mg(-)-3-(2-甲氧苯基)吡咯烷溶于12ml的CH2Cl2中，在0°滴加8.5ml 1M BBr3的CH2Cl2溶液并过夜连续搅拌。反应混合物到入1NNa2CO3溶液，用CH2Cl2萃取并且用盐水洗涤有机相，干燥、蒸发后以比例为88/10.8/1.2的CH2Cl2/EtOH/浓NH4OH水溶液通过硅胶快速色谱法提纯，得到一种油状产品：MS(EI)：M+＝163；NMR(DMSO，120°)：1.85(1H，m)，2.2(1H，m)，2.8(2H，宽)，2.95-3.05(2H，m)，2.2-2.4(2H，m)，3.5(1H，m)，6.7(1H，t)，6.8(1H，d)，7.05(1H，m)，7.1(1H，dd)。
实施例6：1-苄基-3-(5-氯-2-甲氧苯基)吡咯烷
将730mg 1-苄基-3-(5-氯-2-甲氧苯基)吡咯烷-2，5-二酮溶于2ml的乙酰氯中并在室温搅拌24小时。蒸发掉乙酰氯，将残余物干燥后加入295mgLiAlH4在15ml乙醚中的悬浮液中。反应混合物搅拌30分钟，水解、过滤并先在CH2Cl2和2N Na2CO3，之间分配、然后用NaCl水溶液分配。合并的有机相干燥和蒸发后产生一种油，该油经使用1/1的乙酸乙酯/己烷快速色谱法提纯后提供一种无色油状产品：MS(CI)：MH+＝302；NMR(DMSO)：1.7(1H，m)，2.2(1H，m)，2.4-2.8(5H，m)，3.6(2H，q)，3.75(3H，s)，6.95(1H，d)，7.15-7.35(7H，m)。
起始物1-苄基-3-(5-氯-2-甲氧苯基)吡咯烷-2，5-二酮的制备过程如下：
将1.0g2-(5-氯-2-甲氧苯基)琥珀酸悬浮于50ml的二甲苯中，加入0.47ml苄胺，并将该混合物回流8小时以分离水。蒸发溶剂并且用乙酸乙酯溶解残余物，然后依次用2N HCl，2N NaOH和NaCl水溶液萃取。有机层干燥、过滤后蒸发溶剂。干燥的残余物经用1/1的叔丁基甲基醚/己烷快速色谱法提纯后提供一无定形产品：MS(EI)：M+＝329；NMR(DMSO)：2.65(1H，dd)，3.1(1H，dd)，3.45(3H，s)，4.2(1H，dd)，4.6(2H，s)，7.0(1H，d)，7.25-7.4(7H，m)。
其中R0，R1，R2和A具有表中所示含义的下列式I化合物的生产与实施例1近似。在“备注”下标有“A”的化合物优选用与实施例2近似的方法生产，标有“B”的化合物优选用与实施例4或5近似的方法生产，标有“C”的化合物优选用与实施例3近似的方法生产。
  Ex.     R0      R1     R2         A     [αD]       MS  备注
  7     H      OMe     H a；R3＝p-OH，R4＝H     +/-     284(MH+/FAB)
  8     ″      ″     ″ a；R3＝R4＝H     +/-     268(MH+/FAB)   1
  9     ″      ″     ″ a；R3＝o-Cl，R4＝H     +/-     301(M+/EI)
  10     ″      O-CH-(CH3)2     ″ a；R3＝R4＝H     +/-     295(M+/EI)
  11     ″      O-CH2-CH＝CH2     ″ ″     +/-     293(M+/EI)
  12     ″      OMe     ″ a；R3＝m-OMe，R4＝H     +/-     298(MH+/FAB)
  13     ″      ″     ″ a；R3＝p-C(CH3)3；R4＝H     +/-     323(M+/EI)
  14     ″      ″     ″ d；R8＝R9＝H     +/-     273(M+/EI)
  15     ″      ″     ″ b；m＝1，R5＝H     +/-     311(M+/EI)
  16     Me      ″     ″ a；R3＝R4＝H     +/-     281(M+/EI)
  17     H      ″     ″ a；R3＝3-OMe，R4＝5-OMe     +/-     327(M+/EI)   A
  18     ″      ″     ″ d；R8＝苄基-磺酰氨基，R9＝H     +/-     456(M+/EI)
  19     ″      ″     ″ d；R8＝OMe，R9＝H     +/-     303(M+/EI)
  20     ″      ″     ″ e；R10＝-COOC(CH3)3     +/-     375(MH+/ES)
  21     ″      ″     ″ e；R10＝苯甲酰基     +/-     379(MH+/ES)
  22     ″      ″     ″ d；R8＝OH，R9＝Me     +/-     303(M+/EI)
  23     ″      ″     ″ d；R8＝OH，R9＝苯基     +/-     366(MH+/ES)
  24     ″      ″     ″ d；R8＝苯甲酰氨基，R9＝H     +/-     393(MH+/ES)
  25     ″      ″     ″ d；R8＝-NHCOMe，R9＝H     +/-     331(MH+/ES)
  26     ″     ″     ″   a；R3＝p-CH2OH，R4＝H     +/-     298(MH+/ES)  A
  27     ″     ″     ″   a；R3＝p-F，R4＝H     +/-     285(M+/EI)
  28     ″     ″     ″   a；R3＝m-NHSO2-Me，R4＝H     +/-     361(MH+/ES)
  29     ″     ″     ″   a；R3＝p-CON(CH3)2，R4＝H     +/-     338(M+/EI)
  30     ″     ″     5-F   a；R3＝R4＝H     +/-     285(M+/EI)  2
  31     ″     ″     5-Me   ″     +/-     281(M+/EI)  3
  32     ″     ″     5-OMe   ″     +/-     297(M+/EI)
  33     ″     ″     4-OMe   ″     +/-     297(M+/EI)
  34     ″     ″     3-OMe   ″     +/-     297(M+/EI)
  35     ″     ″     H   d；R8＝-NHCO-2-呋喃基，R9＝H     +/-     382(M+/EI)
  36     ″     ″     ″   f；R11＝H     +/-     268(M+/EI)  A
  37     ″     ″     ″   c；R6＝H，R7＝Me     +/-     298(M+/EI)  A
  38     ″     ″     ″   d；R8＝R9＝F     +10.3°(c＝1/EtOH)     309(M+/EI)
  39     ″     ″     6-OMe   a；R3＝R4＝H     +/-     297(M+/EI)
  40     ″     ″     H   c；R6＝H，R7＝环丙基甲基     +19.3°(c＝1/EtOH)     339(MH+/ES)  A
  41     ″     ″     3-Me   a；R3＝R4＝H     +/-     282(MH+/ES)
  42     ″     ″     H   a；R3＝3-OMe，R4＝4-OMe     +25.0°(c＝0.5/EtOH)     328(MH+/CI)
  43     ″     ″     ″   c；R6＝H，R7＝丙基     -18.4°(c＝0.9/EtOH)     327(MH+/ES)  A
  44     ″     ″     ″   a；R3＝m-CON(CH3)2；R4＝H     +19.3°(c＝1/EtOH)     338(M+/EI)
  45     ″      -O-CH2-O-   a；R3＝R4＝H     +/-     281(M+/EI)
  46     ″     OMe    H 四氢吡喃-4-基   +11.4°(c＝1/EtOH)    275(M+/EI)    A
  47     ″     ″    ″ g；X＝O，含X的环处于2，3   +/-    309(M+/EI)    B
  48     ″     ″    ″ g；X＝O，含X的环处于3，4   +20.2°(c＝0.4/EtOH)    326(MH+/CI)
  49     ″     ″    ″ b；m＝3，R5＝H   +24.5°(c＝1/EtOH)    340°
  50     ″     ″    ″ g；X＝CH＝CH，含X的环处于3，4   +11.7°(c＝0.5/EtOH)    320(MH+/ES)
  51     ″     H    ″ b；m＝2，R5＝H   +/-    296(MH+/ES)    B
  52     ″     Me    ″ ″   +/-    309(M+/EI)    B
  53     ″     H    4-OMe c；R6＝H，R7＝异丙基   +/-    326(M+/EI)    C
  54     ″     ″    4-Cl ″   +/-    331(MH+/ES)    C
  55     ″     OMe    5-F ″   +14.5°(c＝1/EtOH)    345(MH+/ES)    C
  56     ″     ″    6-OMe b；m＝2，R5＝H   +/-    356(MH+/ES)    B
  57     ″     OCF3    H ″   +/-    380(MH+/ES)    B
  58     ″     CF3    H ″   +/-    364(MH+/ES)    B
  59     ″     H    4-CF3 ″   +/-    363(M+/EI)    B
  60     ″     OMe    3-Me c；R6＝H，R7＝异丙基   +/-    341(MH+/ES)    C
  61     ″     ″    5-Me b；m＝2，R5＝H   +/-    340(MH+/ES)    4，B
  62     ″     H    4-F c；R6＝H，R7＝异丙基   +32.0°(c＝1/EtOH)    315(MH+/ES)    C
  63     ″     F    H ″   +/-    315(MH+/EI)    C
Me＝甲基
1：Mp＝138°(富马酸氢盐)
2：Mp＝142-144°(富马酸氢盐)
3：Mp＝146-149°(富马酸氢盐)
4：Mp＝164-149°(盐酸盐)

Claims (7)

1.一种呈游离碱或酸加成盐形式的式I化合物
其中
R0是氢或C1-4烷基，
R1是C1-4烷氧基或C2-5链烯氧基，且如果A为式(c)、(e)、(f)或(g)的基团，则R1也可以是卤素、羟基、C1-4烷基、三氟甲基或三氟甲氧基，而如果A是式(c)、(f)或(g)的基团，则R1也可以是氢，
R2是氢、卤素、羟基、C1-4烷基、C1-4烷氧基、C2-5链烯氧基、三氟甲基或三氟甲氧基，或者当处在R1的邻位时也可以与R1形成亚甲二氧基，和A是四氢吡喃-4-基或下式所示基团
Figure C018042340002C2
Figure C018042340002C3
或
Figure C018042340002C4
其中
X是O、S或CH＝CH，
R6是氢、卤素或C1-4烷基，
R7是氢、C1-6烷基或C3-7环烷基C1-4烷基，
R8是氢、卤素、羟基、C1-4烷基、C1-4烷氧基、氨基、C2-5链烷酰基氨基、苯甲酰氨基、C1-4烷基磺酰氨基、苄基磺酰氨基、呋喃基羰基氨基、氨基甲酰基、C1-4烷基氨基甲酰基或二C1-4烷基氨基甲酰基和R9是氢、卤素、C1-4烷基或苯基，或
R8和R9一起为-O-(CH2)m-O-，其中m是1-3，R10是氢、C1-4烷基、C3-6环烷基C1-4烷基、C1-4烷基羰基、C3-6环烷基羰基、C1-4烷氧羰基、苄基、苄氧基羰基、苯甲酰基、C1-4烷基磺酰基、苯磺酰基、苄基羰基、苄基磺酰基、2-呋喃基羰基氨基或N-C1-4烷基-N-(2-呋喃基羰基)氨基，和
R11是氢或C1-4烷氧基。
2.如权利要求1所定义的式I化合物的游离碱或酸加成盐，其中A为式(c)的基团。
3.(+)-1-异丙基-5-[3-(2-甲氧苯基)吡咯烷-1-基甲基]-1H-吡啶-2-酮的游离碱或酸加成盐。
4.(+)-1-异丙基-5-[3-(4-氟苯基)吡咯烷-1-基甲基]-1H-吡啶-2-酮的游离碱或酸加成盐。
5.一种生产如权利要求1定义的式I化合物的方法，包括烷基化式II化合物
其中R1和R2如权利要求1定义，并以游离碱或酸加成盐形式回收所得化合物。
6.一种药物组合物，包含与药物载体或稀释剂结合的权利要求1-4任一项要求的化合物的游离碱或可药用酸加成盐。
7.权利要求1-4任一项要求的化合物的游离碱或可药用酸加成盐在制造用于治疗任何对α2肾上腺素受体拮抗剂有反应的疾病的药物中的用途。
CNB018042341A 2000-01-28 2001-01-26 用作α-2-肾上腺素受体拮抗剂的1,3-二取代吡咯烷 Expired - Fee Related CN1178935C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0002100.6A GB0002100D0 (en) 2000-01-28 2000-01-28 Organic compounds
GB0002100.6 2000-01-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100839164A Division CN1305847C (zh) 2000-01-28 2001-01-26 用作α－2－肾上腺素受体拮抗剂的1,3－二取代吡咯烷

Publications (2)

Publication Number Publication Date
CN1396920A CN1396920A (zh) 2003-02-12
CN1178935C true CN1178935C (zh) 2004-12-08

Family

ID=9884609

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB018042341A Expired - Fee Related CN1178935C (zh) 2000-01-28 2001-01-26 用作α-2-肾上腺素受体拮抗剂的1,3-二取代吡咯烷
CNB2004100839164A Expired - Fee Related CN1305847C (zh) 2000-01-28 2001-01-26 用作α－2－肾上腺素受体拮抗剂的1,3－二取代吡咯烷

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2004100839164A Expired - Fee Related CN1305847C (zh) 2000-01-28 2001-01-26 用作α－2－肾上腺素受体拮抗剂的1,3－二取代吡咯烷

Country Status (28)

Country Link
US (1) US7012085B2 (zh)
EP (1) EP1257547B1 (zh)
JP (1) JP2003523353A (zh)
KR (1) KR20020069375A (zh)
CN (2) CN1178935C (zh)
AR (1) AR029463A1 (zh)
AT (1) ATE384715T1 (zh)
AU (1) AU768844B2 (zh)
BR (1) BR0107888A (zh)
CA (1) CA2398794C (zh)
CO (1) CO5261521A1 (zh)
CZ (1) CZ20022581A3 (zh)
DE (1) DE60132558T2 (zh)
ES (1) ES2296763T3 (zh)
GB (1) GB0002100D0 (zh)
HU (1) HUP0203836A3 (zh)
IL (1) IL150550A0 (zh)
MX (1) MXPA02007318A (zh)
MY (1) MY128639A (zh)
NO (1) NO20023485L (zh)
NZ (1) NZ520342A (zh)
PE (1) PE20011068A1 (zh)
PL (1) PL202473B1 (zh)
PT (1) PT1257547E (zh)
RU (1) RU2002121646A (zh)
SK (1) SK10802002A3 (zh)
WO (1) WO2001055132A1 (zh)
ZA (1) ZA200205991B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305847C (zh) * 2000-01-28 2007-03-21 诺瓦提斯公司 用作α－2－肾上腺素受体拮抗剂的1,3－二取代吡咯烷

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436972B1 (en) 2000-04-10 2002-08-20 Dalhousie University Pyridones and their use as modulators of serine hydrolase enzymes
WO2003082275A1 (en) * 2002-03-29 2003-10-09 Orion Corporation Treatment of dependence and dependence related withdrawal symptoms
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
JP2008037850A (ja) * 2006-08-10 2008-02-21 Mitsubishi Tanabe Pharma Corp 新規置換ピペリジン誘導体
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
US8273900B2 (en) * 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5634506B2 (ja) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ， インコーポレイテッド １，２，３−トリアゾロ［４，３−ａ］ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
GB2503187A (en) * 2011-09-15 2013-12-25 Univ Sussex Composition for use in the treatment of neurodevelopmental disorders
WO2014080290A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
KR20150096794A (ko) * 2012-12-21 2015-08-25 제니쓰 에피제네틱스 코포레이션 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
US9636328B2 (en) 2013-06-21 2017-05-02 Zenith Epigenetics Ltd. Substituted bicyclic compounds as bromodomain inhibitors
CN109939113B (zh) 2013-06-21 2022-02-15 恒翼生物医药科技(上海)有限公司 双环溴结构域抑制剂
CA2919948C (en) 2013-07-31 2020-07-21 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
LT3096790T (lt) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
WO2016087936A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridinones as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI95572C (fi) 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US5185364A (en) 1988-01-15 1993-02-09 Abbott Laboratories Aminomethyl-chroman and -thiochroman compounds
AU653837B2 (en) 1991-04-17 1994-10-13 Pharmacia & Upjohn Company Substituted phenylazacycloalkanes as CNS agents
GB9113031D0 (en) 1991-06-17 1991-08-07 Smithkline Beecham Plc Compounds
FR2687146B1 (fr) * 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ATE243196T1 (de) 1994-03-09 2003-07-15 Novo Nordisk As Piperidine und pyrrolidine
SE9802546D0 (sv) 1998-07-15 1998-07-15 Ross Nicholas Waters Medicinal product and method for treatment and prevention of dyskinesia
IT1303737B1 (it) 1998-11-11 2001-02-23 Smithkline Beecham Spa Derivati fenilpiperidinici procedimento per la loro preparazione eloro uso come ligandi del recettore orl-1.
GB0002100D0 (en) * 2000-01-28 2000-03-22 Novartis Ag Organic compounds

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1305847C (zh) * 2000-01-28 2007-03-21 诺瓦提斯公司 用作α－2－肾上腺素受体拮抗剂的1,3－二取代吡咯烷

Also Published As

Publication number Publication date
AR029463A1 (es) 2003-07-02
HUP0203836A3 (en) 2005-03-29
CZ20022581A3 (cs) 2002-10-16
RU2002121646A (ru) 2004-01-10
PL202473B1 (pl) 2009-06-30
GB0002100D0 (en) 2000-03-22
WO2001055132A1 (en) 2001-08-02
PE20011068A1 (es) 2001-11-15
ATE384715T1 (de) 2008-02-15
ES2296763T3 (es) 2008-05-01
AU2850101A (en) 2001-08-07
KR20020069375A (ko) 2002-08-31
PL356265A1 (en) 2004-06-28
MXPA02007318A (es) 2002-12-13
NZ520342A (en) 2004-08-27
CA2398794C (en) 2009-12-08
PT1257547E (pt) 2008-04-23
HUP0203836A2 (hu) 2003-03-28
CN1396920A (zh) 2003-02-12
NO20023485L (no) 2002-09-03
BR0107888A (pt) 2002-11-05
EP1257547A1 (en) 2002-11-20
IL150550A0 (en) 2003-02-12
DE60132558T2 (de) 2009-02-19
MY128639A (en) 2007-02-28
US7012085B2 (en) 2006-03-14
SK10802002A3 (sk) 2003-01-09
EP1257547B1 (en) 2008-01-23
NO20023485D0 (no) 2002-07-22
JP2003523353A (ja) 2003-08-05
DE60132558D1 (de) 2008-03-13
CN1636977A (zh) 2005-07-13
CO5261521A1 (es) 2003-03-31
CA2398794A1 (en) 2001-08-02
US20030008874A1 (en) 2003-01-09
AU768844B2 (en) 2004-01-08
CN1305847C (zh) 2007-03-21
ZA200205991B (en) 2003-10-07

Similar Documents

Publication Publication Date Title
CN1178935C (zh) 用作α-2-肾上腺素受体拮抗剂的1,3-二取代吡咯烷
CN1083443C (zh) 吲哚衍生物
CN1671377A (zh) 作为大麻素－cb1受体配体的1h－1,2,4－三唑－3－酰胺衍生物
EA010234B1 (ru) Производные тетрагидроизохинолилсульфонамидов, их получение и применение в терапии
CN1044909C (zh) 吲哚衍生物
CN1054844C (zh) N－取代的氮杂二环庚烷衍生物、它们的制备及应用
CN1152857C (zh) 用作多巴胺受体的苯磺酰胺-苯乙胺
CN1056880A (zh) 新的吡啶并[2，3-f][1，4]硫代吖庚因和吡啶并[3，2-b][1，5]苯并硫代吖庚因
ZA200207381B (en) Hydroxyphenyl-piperazinyl-methyl-benzamide derivatives for the treatment of pain.
CN1268938A (zh) 氨基环烷烃化合物
CN1014992B (zh) 喹唑啉二酮和吡啶并嘧啶二酮的制备方法
CN100335483C (zh) 具有镇痛作用的新型双哌嗪季铵盐类化合物
CN1039245A (zh) 一种新颖噻吩衍生物和其制备方法
CN1136201C (zh) 药理活性的对映体及其制备方法
CN100341874C (zh) 异喹啉－3－甲酸酰胺及其药物用途
WO2016027757A1 (ja) 新規２－アミノベンゾイル誘導体
US20240010628A1 (en) Methods of manufacture of r-mdma
CN1138753C (zh) 二甲基取代的环己二烯衍生物
JP2008013558A (ja) 新規ナフタレン化合物、その製造法、およびそれを含有する薬学的組成物
KR20200029393A (ko) 오렉신 수용체 길항제
CN1248249A (zh) 多巴胺激动剂5－氨基烷氧基－1,4－二氢喹喔啉－2,3－二酮类化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20041208

Termination date: 20110126